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Summary.-Subcutaneous growth of immunogenic chemically induced rat sarco-
mata and a hepatoma was restricted when cells were injected into syngeneic animals
in admixture with MER. Rats rejecting mixed inocula were immune to further
challenge with the same tumour. Growth of a chemically induced mammary
carcinoma which lacks detectable immunogenicity was suppressed when low cell
inocula were injected in admixture with MER or intact BCG organisms, although
animals were not immdne to re-challenge. These studies indicate that clinically
MER may be a suitable alternative to BCG for contact suppression of tumour growth
or incorporation into tumour cell: adjuvant vaccines for active immunotherapy.
GROWTH of many syngeneically trans-
planted animal tumours is suppressed by
in vivo contact with intact Bacillus
Calmette Gue6rin (BCG) organisms. For
example, injection of tumour cells in
admixture with viable BCG vaccine re-
stricts growth of 3-methylcholanthrene
(Mc) induced sarcomata of mice and
rats (Baldwin and Pimm, 1971, 1973a;
Bartlett, Zbar and Rapp, 1972), a rat
epithelioma (Baldwin and Pimm, 1973b),
hepatomata induced in the guinea-pig
with diethylnitrosamine (Zbar, Bernstein
and Rapp, 1971; Bartlett and Zbar,
1.972) and in rats with 4-dimethyl-
aminoazobenzene (Baldwin et al., 1974).
Mixed inocula of tumour cells and BCG
which fail to develop induce specific
host immunity and can be used for active
immunotherapy of subcutaneous growths
of sarcomata and hepatomata in rats,
mice and guinea-pigs (Baldwin and Pimm,
1973a; Bartlett and Zbar, 1972) and to
treat pulmonary tumour deposits of rat
sarcomata (Baldwin and Pimm, 1973c).
In addition, intrapleural and intraperi-
toneal injection of BCG restricts growth
of rat tumours transplanted into these
sites (Pimm and Baldwin, 1975), and the
intravenous injection of BCG organisms
into pulmonary tissue suppresses growth
in the lungs of intravenously injected
rat sarcoma cells and pulmonary meta-
stases from a rat epithelioma (Baldwin
and Pimm, 1973b, c) and primary rat
hepatomata (Baldwin and Pimm, 1974).
Clinically, suppression of tumour
growth by this form of BCG contact
therapy has so far been limited mainly
to surface tumours, particularly melanoma
(Morton et al., 1970; Bornstein et al.,
1973; Pinsky, Hirshaut and Oettgen,
1973). In addition, mixed inocula of
malignant cells and BCG are being used
for active immunotherapy ofsolid tumours
(Sparks et al., 1973) and myelocytic
leukaemia (Sokal, Aungst and Grace,
1973). However, adverse side - effects
occur in patients undergoing immuno-
therapy employing standard BCG vac-
cines containing a proportion of viable
organisms (Pinsky et al., 1973; Sparks et
al., 1973; Hunt et al., 1973). Clearly
non-living, non-toxic mycobacterial mate-
rials capable ofsuppressing tumourgrowth
will be needed for significant extension
of this form of treatment in humans.
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rat tumours were carried out to assess
the tumour suppressive property of the
methanol extraction residue (MER) of
BCG, originally described by Weiss and
Wells (1960). Its tumour suppressive
properties when injected in admixture
with cells of immunogenic sarcomata
and a hepatoma have been examined,
since these tumours are known to be
suppressed when injected in admixture
with intact BCG organisms (Baldwin and
Pimm, 1973a; Baldwin et al., 1974).
In addition, the ability of intact BCG
and MER to suppress growth of a trans-
planted mammary carcinoma which lacks
detectable immunogenicity has been
examined.
MATERIALS AND METHODS
Tumours.-All tumours were induced
chemically in inbred Wistar rats and main-
tained by subcutaneous transplantation in
syngeneic animals of the same sex as the
primary host. Sarcomata Mc7 and Mc57,
induced by 3-methylcholanthrene, are highly
immunogenic, rats immunized by surgical
excision of transplanted tumours rejecting
challenge with up to 5 x 106 cells of the
immunizing sarcoma. Mammary carcinoma
AAF 57, induced by repeated intraperitoneal
injection of N-hydroxy-2-acetylaminofluo-
rene, lacks significant immunogenicity, since
rats immunized by surgical excision will not
reject a challenge inoculum of 1 x 103 cells,
the lowest number required for consistent
growth in normal syngeneic animals. Hepa-
toma D23, induced by oral administration
of4-dimethylaminoazobenzene, is moderately
immunogenic, immunized animals rejecting
challenge with up to 5 X 105 cells after
subcutaneous graft excision.
Single tumour cell suspensions were pre-
pared by digestion of finely minced tumour
fragments with 0-25% trypsin in Hanks'
balanced salt solution and dispersed, after
washing, in Medium 199.
Methanol extraction residue (MER).-The
methanol insoluble fraction of phenol killed,
acetone washed Phipps Strain BCG (NSC
143769, Lot 675738-00607) was supplied as
a desiccated powder by the Division of
Cancer Treatment, National Cancer Institute,
Bethesda, Maryland. It was reconstituted
with physiological saline by grinding in a
Potter homogenizer. The resulting suspen-
sion was stored at -20°C in 1 ml aliquots
at a concentration of 1 mg dry wt/ml and
sterilized by heating to 70(C for 15 min
before use (Weiss, 1972).
Bacillus Calmette Guerin (BCG). Freeze
dried BCG vaccine (percutaneous) was sup-
plied by Glaxo Research Ltd, Greenford,
Middlesex. On reconstitution in water ap-
proximately 20% of organisms were viable,
giving 3 x 108 viable organisms in 10 mg
moist weight of organisms/ml.
Experimental protocol.-To determine the
influence of intact viable BCG organismns
or MER on tumour growth, defined numbers
of tumour cells were mixed with known
amounts of either MER, expressed as mg
dry weight, or BCG, expressed as mg moist
weight of organisms, and immediately in-
jected subcutaneously into syngeneic reci-
pients. In one test, tumour cells were
inoculated subcutaneously and MER was
injected intraperitoneally. In some cases,
rats which had rejected mixed inocula of
tumour cells and MER were subsequently
rechallenged with cells of the same tumour.
RESULTS
Tests on the growth inhibition of
sarcomata and a hepatoma following
contact with MER are summarized in
Table I. In the first series of tests
(Experiments 1-3), inocula of 1 x 106 to
1 x 107 sarcoma Mc7 cells were com-
pletely suppressed by contacting with
200 ,g of MER, whereas tumour cell
inocula alone produced progressive growth
in all but one control rat. In contrast,
injection of the same quantity of MER
intraperitoneally did not restrict the
subcutaneous growth of 1 x 106 Mc7
cells (Experiment 4). With the second
sarcoma, Mc57, admixture of 1 X 106
cells with 50-200 ug of MER prevented
growth in all rats, and as little as 10 fug
suppressed growth in 4/5 animals (Ex-
periment 5).
Hepatoma D23 was also suppressed
when injected together with MER. In
Experiment 6, while 1 x 105 cells alone
produced progressively growing tumours
in 4/5 rats, a mixed inoculum of 1 x 105
cells and 200 ,ig of MER grew out in
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TABLE I. Influence of Methanol Extraction Residue of BCG (MER) on Growth
ofSubcutaneously Transplanted Rat Tumour Cells
Expt
1
2
3
Tumour
Sarcoma AMc7
Sarcoma Mc7
Sarcoma Mc7
4 Sarcoma Mc7
5 Sar-coma AMc57
6 Hopatoma D23
7 HHepatoma D23
No. of cells
injectedl
1 X 106
2 x 106
2 x 106
.5x 106
1 x 107
1 X 106
1 x 106
1 X 106
1 X 106
] x 106
1 x 10'4
1 x 105
MTER treatment
= A
jig
200
200
200
200
200
200
10
50
100
200
200
200
Route*
Admixture
Admixture
Admixture
Admixture
Admixture
I.P.
Admixture
Admixture
Admixture
Admixture
Admixture
Admixture
Tumour takes in:
Test
0/11
0/6
0/5
0/.;
0/5
5/5
1/5-
I/5
0/.
0/., J
2/10)
(/10
Conitrol
'/10
6/6
,Ir
5/5
4/5
4/5
51.5
* Admixture-cells an(l MER mixe(d together.
I.P. AIER iinjectedl intraperitoneally.
only 2/10 animals; tumour growth in
these rats was markedly retarded so that
after 25 days mean tumour diameter in
control rats was approximately 3 cm
whereas the tumours in treated animals
were 0.5 and 1 0 cm mean diameters.
In the second test with hepatoma D23
(Experiment 7) growth from 1 x 105
cells was completely suppressed in all
(10/10) rats by admixture with 200 /,g
of MER.
In similar tests with mammary car-
cinoma AAF 57, which lacks detectable
immunogenicity, subcutaneous challenges
with low cell inocula were suppressed by
contacting with BCG percutaneous vac-
cine, or MER (Table II). In the first
test, an inoculum of 1 x 103 cells in
admixture with 200 Itg moist weight of
BCG organisms grew out in only 1/5
rats, compared with 5/5 takes in controls.
With inocula of 5 x 103 and 1 x 104
cells, growth was suppressed in 4/10 and
and 6/12 animals respectively, although
1 x 105 cells was not controlled, even
where 10 mg moist weight of BCG was
added to the challenge inoculum. In
similar tests with MER, the ability of the
preparation to restrict growth of 1 x 104
and 2 x 104 cells was investigated and
with both inocula, tumour development
was prevented in the majority of rats
(total 16/20) compared with takes in all
control animals.
TABLE II.-Subcutaneous Growth of Mam-
mary Carcinoma AAF 57 Cells in
Admixture with BCG, orl Methanol Ex-
traction Residue (MER)
Mixed subcuttaneouis inoctilum
No. of
tumour
cells
1 x 103
5,x 103
1 x 104
1 x 105
1x 105
1 x 104
2x 104
Mycobact4
preparati
Alaterial Do
BCG
BCG
B3CG
BCG
1BCG I
AIER
MER
erial
ion Ttuniou takes in:
Se (lig)* Test Control
200 1/5 5/5
20() 6/10 10/11
200 6/12 12/12
200 6/6 6/6
10(()( 4/4 4/4
200 2/10 10/1(
200 2/10 11/l
* Moist weight BCG organisms, or (Iry weight
of MER.
Animals which had rejected mixed
inocula of MER and cells of sarcoma
Mc7, hepatoma D23 or mammary car-
cinoma AAF 57 were subsequently re-
challenged with cells of the same tumour
(Table III). With sarcoma Mc7 and
hepatoma D23, animals exhibited signi-
ficant levels of tumour immunity, as
evidenced by reduced tumour takes com-
pared with control rats. In contrast,
rats rejecting mixed inocula of 1 x 104
or 2 x 104 AAF 57 cells and MER were
unable to reject re-challenge with as few
as 5 x 103 cells.
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TABLE III. Tumour Transplantation Resistance Induced by Tumour Cells Mixed
with Methanol Extraction Residue of BCG
Tumour
Sarcoma Mc7
Hepatoma D23
Mammary carcinoma AAF 57
Immunizing inoculum
No. of cells [ig MER
1 x 106
1 x 107
1 x 105
1 x 105
1 x 104
2 x 104
200
200
200
200
200
200
Challenge inoculum
Tumour No. of cells
Mc7
Mc7
D23
D23
AAF 57
AAF 57
1 x 106
1 x 106
5 x 103
5 x 103
5 x 103
5 x 103
Takes in:
Test Control Test Control
2/10
1/4
3/7
4/8
5j25
10/10
6/6
4/5
5/5
5/5
DISCUSSION
The methanol extraction residue of
BCG (MER), originally described by
Weiss and Wells (1960) is the residue
from methanol extraction of phenol killed,
acetone washed BCG organisms. Its phy-
sical and biological properties have re-
cently been reviewed by Weiss (1972).
Predominant among its characteristics is
the ability of MER, when injected by a
variety of routes, to act as a general
immunostimulant and suppress growth of
a number oftransplanted animal tumours.
MER has the advantage, compared with
intact BCG organisms, that it is non-
living and therefore non-infectious, it is
not pyrogenic and only poorly induces
tuberculin hypersensitivity even in guinea-
pigs or humans. Clinically, MER is
currently being used in the immuno-
therapy of myeloid leukaemia (Weiss,
1972).
The present studies demonstrate that
localized MER may exert a pronounced
tumour suppressive effect, so that sub-
cutaneous growth of immunogenic trans-
planted rat sarcomata and a hepatoma
is restricted when cells are injected in
admixture with MER and this leads to
the development of a tumour specific
host immunity. These observations are
comparable with previous findings with
viable BCG vaccine containing intact
organisms (Baldwin and Pimm, 1971,
1973a; Baldwin et al., 1974). In the
present studies, a single intraperitoneal
injection of MER did not suppress sub-
cutaneous growth of sarcoma Mc7, and
this too is in keeping with suppression
mediated by intact organisms, where
contact between sarcoma cells and BCG
is also essential for controlling growth
of this type of tumour (Baldwin and
Pimm, 1971).
In addition to suppressing growth
of immunogenic tumours, BCG or MER
in admixture with low cell inocula of
the non-immunogenic chemically induced
mammary carcinoma AAF 57 restricted
subcutaneous tumour growth. Rats re-
jecting mixed inocula of cells and MER
were not, however, subsequently immune
to re-challenge with this tumour. In
similar studies with a diethylnitrosamine
induced guinea-pig hepatoma, Zbar et
al. (1971) reported that mixed inocula of
tumour cells and BCG failed to develop
although this tumour was not demon-
strably immunogenic by conventional
immunization techniques. In contrast to
the present findings, however, guinea-pigs
rejecting these mixed inocula were subse-
quently immune to further challenge with
the same hepatoma.
The present studies, demonstrating
that MER contacted with tumour cells
may suppress their growth, extends the
number of non-living adjuvants available
for clinical application of this type of
treatment although MER may have ad-
vantages compared with other myco-
bacterial preparations. Heat killed BCG
inhibits growth of murine sarcomata
(Chung, Zbar and Rapp, 1973), but it
still elicits tuberculin hypersensitivity.
Moreover it is not consistently tumour
suppressive since it does not control
growth of guinea-pig hepatomata (Zbar et
al., 1971). Radiation sterilized BCG has
also been employed to suppress subcu-
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taneous and pulmonary growth of rat
tumour cells (Baldwin et al., 1974), but
again this material still induces tuberculin
reactions and hepatic granulomata in the
guinea-pig. In addition, cell wall frag-
ments of BCG retain tumour suppressive
properties of the intact organisms, but
only if attached to the surface of oil
droplets in aqueous emulsions (Zbar,
Rapp and Ribi, 1972; Baldwin and Pimm,
1973d).
Weiss (1974) has recently reported
that intralesional injections of MER into
transplanted murine sarcomata and a
guinea-pig hepatoma may restrict tumour
development. Further tests are therefore
in progress with rat tumours described
in this paper to compare the tumour
suppressive properties of MER with those
of intact viable or radiation killed BCG.
These include tumour suppression by
intralesional injections; ability of intra-
peritoneally and intrapleurally injected
organisms to control tumour growth at
these sites; the influence of intravenously
injected vaccine on pulmonary meta-
stasis; and the use of mixed inocula of
BCG and tumour cells for active immuno-
therapy of pulmonary and subcutaneous
tumour deposits. However, the implica-
tion from the present studies is that MER
can replace intact BCG organisms in
these situations, and may therefore serve
as a suitable mycobacterial preparation
for clinical applications of this type of
tumour therapy, hopefully without the
adverse side-effects currently being en-
countered in immunotherapy with intact,
living BCG.
This work was supported by the
Cancer Research Campaign. We thank
Dr H. B. Wood, National Cancer Institute,
for the supply of MER, and Glaxo
Research Ltd for BCG.
REFERENCES
BALDWIN, R. W. & PIMM, AI. V. (1971) Influence
of BCG Infection on Growth of 3-methylchol-
anthrene-induced Rat Sarcomas. Eur. J. din.
biol. Res., 16, 875.
BALDWIN, R. W. & PIMM, AI. V. (1973a) BCG
Immunotherapy of a Rat Sarcoma. Br. J.
Cancer, 28, 281.
BALDWIN, R. W. & PiMM, AI. V. (1973b) BCG
Immunotherapy of Local Subcutaneous Growths
and Post-surgical Pulmonary Metastases of a
Transplanted Rat Epithelioma of Spontaneous
Origin. Int. J. Cancer, 12, 420.
BALDWIN, R. W. & PIMM, M. V. (1973c) BCG
Immunotherapy of Pulmonary Growths from
Intravenously Transferred Rat Tumour Cells.
Br. J. Cancer, 27, 48.
BALDWIN, R. W. & PIMM, AM. V. (1973d) BCG
Immunotherapy of Rat Tumors of Defined
Immunogenicity. Natn. Can?cer Inst. Monog.,
39, 11.
BALDWIN, R. W. & PIMM, M. V. (1974) BCG Sup-
pression of Pulmonary Metastases from Primary
Rat Hepatomata. Br. J. Cancer, 30, 473.
BALDWIN, R. W., COOK, A. J., HOPPER, D. G. &
PiMM, M. V. (1974) Radiation-killed BCG in
the Treatment of Transplanted Rat Tumour.
Int. J. Cancer, 13, 743.
BARTLETT, G. L. & ZBAR, B. (1972) Tumor-specific
Vaccine Containing Mycobacteriumn bovis and
Tumor Cells: Safety and Efficacy. J. natn.
Cancer Inst., 48, 1709.
BARTLETT, G. L., ZBAR, B. & RAPP, H. J. (1972)
Suppression of Mlurine Tumor Growth by Immune
Reaction to the Bacillus Calmette-Guerin Strain
of Mycobacterirmn bovis. J. natn. Cancer Inst.,
48, 245.
BORNSTEIN, R. S., MASTRANGELO, M. J., SULIT, H.,
CHEE, D., YARBRO, J. W., PREHN, L. M. &
PREHN, R. T. (1973) Immunotherapy ofMelanoma
with Intralesional BCG. Natn. Cancer Inst.
Monog., 39, 213.
CHUNG, E. B., ZBAR, B. & RAPP, H. J. (1973)
Tumor Regression Mediated by MycobacteriumTb
bovis (Strain BCG). Effects of Isonicotinic Acid
Hydrazide, Cortisone Acetate, anid Antithymocyte
Serum. J. natn. Cancer Inist., 51, 241.
HUNT, J. S., SILVERSTEIN, M. J., SPARKS, F. C.,
HASKELL, C. M., PILCH, Y. H. & MORTON, D. L.
(1973) Granulomatous Hepatitis: A Complication
of BCG Immunotherapy. Lancet, ii, 820.
AMORTON, D. L., EILBER, F. R., JOSEPH, W. L.,
WOOD, W. C., TRAHAN, E. & KETCHAM, A. S.
(1970) Immunological Factors in Human Sarcomas
and Melanomas. A Rational Basis for Immuno-
therapy. Antn. Surg., 172, 740.
PIMM, M. V. & BALDWIN, R. W. (1975) BCG Therapy
of Pleural and Peritoneal Growths of Trans-
planted Rat Tumours. Int. J. Cancer. In
the press.
PINSKY, C. M., HIRSHAUT, Y. & OETTGEN, H. F.
(1973) Treatment of Malignant Melanoma by
Intratumoral Injection of BCG. Natn. Cancer
Inst. Monog., 39, 225.
SOKAL, J. E., AUNGST, C. W. & GRACE, J. T. (1973)
Immunotherapy in Well Controlled Chronic
Myelocytic Leukemia. NVew York State J.
Med., 73, 1180.
SPARKS, F. C., SILVERSTEIN, M. J., HUNT, J. S.,
HASKELL, C. M., PILCH, Y. H. & MORTON, D. L.
(1973) Complications of BCG Immunotherapy in
Patients with Cancer. NVew. Engl. J. Med.,
289, 827.
WEISS, D. W. (1972) Nonspecific Stimulation and
Modulationi of the Immune Response and ofBCG IN THE TREATMENT OF TRANSPLANTED RAT TUMOURS 181
States of Resistance by the Methanol-extraction
Residue of Tubercle Bacilli. Natn. Cancer Inst.
Monog., 35, 157.
WEISS, D. W. (1974) Immunological Intervention
in Neoplasia. In The Role of Immunological
Factors in Viral and Oncogenic Processes. Eds.
R. F. Beers, R. C. Tilghman and E. G. Bassett.
Baltimore: Johns Hopkins University Press.
WEIss, D. W. & WELLS, A. Q. (1960) Vaccination
against Tuberculosis with Non-living Vaccine.
III. Vaccination of Guinea Pigs with Fractions
of Phenol-killed Tubercle Bacilli. Am. Rev.
resp. Di8., 82, 339.
ZBAR, B., BERNSTEIN, I. D. & RAPP, H. J. (1971)
Suppression of Tumor Growth at the Site of
Infection with Living Bacillus Calmette Guerin.
J. natn. Cancer Indt., 46, 831.
ZBAR, B., RAPP, H. J. & RIBI, E. E. (1972) Tumor
Suppression by Cell Walls of Mycobacterium
bovi8 Attached to Oil Droplets. J. natn. Cancer
Inst., 48, 831.
14